-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

613.O1.6 613. Acute Myeloid Leukemia: Novel Therapies and Treatment Approaches

Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
AML, Biological, antibodies, Adult, Leukemia, Diseases, Combinations, Therapies, MDS, Study Population, Myeloid Malignancies, Clinically relevant, TKI, stem cells
Sunday, December 6, 2020: 9:30 AM-11:00 AM
Moderators:
Sameem Abedin, MD, Medical College of Wisconsin and Monica L. Guzman, PhD, Weill Cornell Medical College Division of Hematology/Oncology
Disclosures:
Abedin: Helsinn Healthcare: Honoraria; Agios: Honoraria; Jazz Pharmaceuticals: Honoraria; Pfizer: Research Funding; Helsinn Healthcare: Research Funding; Actinium Pharmaceuticals: Research Funding.
9:30 AM

David A. Sallman, MD1, Adam S. Asch, MD2, Suman Kambhampati, MD3*, Monzr M. Al Malki, MD4, Joshua F. Zeidner, MD5, William Donnellan, MD6, Daniel J. Lee, MD7, Paresh Vyas, MRCP, FRCP, FRCPath8, Deepa Jeyakumar, MD9, Gabriel N. Mannis, MD10, Tiffany N Tanaka, MD11, Wanxing Chai-Ho, MD12, Richard A. Larson, MD13, Andrew R. Whiteley, MD14, Guido Marcucci, MD4, Rami S. Komrokji, MD1, Guillermo Garcia-Manero, MD15, Joanna Van Elk16*, Ming Lin, PhD16*, Roy Maute, PhD16*, Jens-Peter Volkmer, MD16*, Chris H. Takimoto, MD, PhD16*, Mark P. Chao, MD, PhD16* and Naval Daver, MD15

1H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
2Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK
3HCA Midwest Health at Research Medical Center, Kansas City, MO
4City of Hope, Duarte, CA
5Lineberger Comprehensive Cancer Center, Chapel Hill, NC
6Tennessee Oncology / Sarah Cannon Research Institute, Nashville, TN
7Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY
8University of Oxford, Oxford, United Kingdom
9University of California Irvine, Chao Family Comprehensive Cancer Center, Orange, CA
10Division of Hematology, Department of Medicine, Stanford University, Stanford, CA
11Moores Cancer Center, University of California San Diego, San Diego, CA
12Division of Hematology/Oncology, Department of Medicine, University of California, Los Angeles, Los Angeles, CA
13Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
14Baylor University Medical Center, Dallas, TX
15MD Anderson Cancer Center, Houston, TX
16Gilead Sciences, Inc., Foster City, CA

9:45 AM

Ibrahim Aldoss, MD1, Geoffrey L Uy, MD2, Norbert Vey, MD3, Ashkan Emadi, M.D., Ph.D.4, Peter H. Sayre, MD, PhD5, Roland B. Walter, MD, PhD, MS6, Matthew C Foster, MD7, Martha L. Arellano, MD8, John E. Godwin, MD9, Matthew J. Wieduwilt, MD, PhD10, Michael T. Byrne, DO11, Laura C. Michaelis, MD12, Patrick J. Stiff, MD13, Matteo Giovanni Carrabba, MD14*, Patrice Chevalier, MD, PhD15*, Emmanuel Gyan, MD, PhD16, Christian Recher, MD, PhD17, Anjali S Advani, MD18, Martin Wermke19*, Harry P. Erba20, Fabio Ciceri, MD21*, Geert Huls, MD, PhD22, Mojca Jongen-Lavrencic, MD, PhD23, Max S. Topp, MD24, Antonio Curti, MD PhD25, Farhad Ravandi, MBBS26, Michael P. Rettig, PhD27, John Muth, MS28*, Mary Beth Collins29*, Erin Timmeny30*, Kuo Guo, MSc31*, Jian Zhao, PhD31*, Kathy Tran28*, Patrick Kaminker, PhD32*, Priyanka Patel, PharmD29*, Ouiam Bakkacha, MD33*, Teia Curtis34*, Kenneth Jacobs, MD35*, Maya Kostova, PhD31*, Jennifer Seiler, PhD, RAC29*, Bob Lowenberg, MD, PhD36, Sergio Rutella, MD, PhD, FRCPath37, Ezio Bonvini, MD32, Jan K Davidson-Moncada, MD, PhD38 and John F. DiPersio, MD2

1Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA
2Washington University School of Medicine, Saint Louis, MO
3Hematologie clinique, Institut Paoli Clamettes, Marseille, France
4University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD
5University of California, San Francisco, San Francisco, CA
6Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
7Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, Chapel Hill, NC
8Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA
9Providence Portland Medical Center, Portland, OR
10Moores Cancer Center, University of California, San Diego, La Jolla, CA
11Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN
12Division of Hematology/Oncology, Department of Medicine, The Medical College of Wisconsin Inc., Milwaukee, WI
13Loyola University Chicago Stritch School of Medicine, Maywood, IL
14Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
15Department of Hematology and Cell Therapy, CHU Nantes, Nantes, France
16CHU de Tours - Hôpital Bretonneau, Tours, France
17Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
18Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH
19NCT/UCC Early Clinical Trial Unit, University Hospital Carl Gustav Carus, Dresden, Germany
20Duke University School of Medicine, Durham, NC
21Haematology and BMT Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
22Department of Hematology, University Medical Center Groningen, Groningen, GZ, Netherlands
23Erasmus University Medical Center, Rotterdam, Netherlands
24Medizinische Klinik Und Poliklinik II, Universitätsklinikum Würzburg, Würzburg, Germany
25Hematology/Oncology "L. e A. Seràgnoli", Sant’Orsola-Malpighi University Hospital, Bologna, Bologna, Italy
26Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
27Department of Internal Medicine, Division of Oncology, Washington Univ. School of Med., Saint Louis, MO
28MacroGenics, Inc., Rockville, MD
29MacroGenics, Rockville
30MacroGenics, Inc., ROCKVILLE, MD
31MacroGenics, Rockville, MD
32Macrogenics, Rockville, MD
33Macrogenics,Inc, ROCKVILLE, MD
34MacroGenics, Inc., Frederick, MD
35MacroGenics, Inc, Rockville, MD
36Department of Hematology, Erasmus University Medical Center, Rotterdam, Netherlands
37John van Geest Cancer Centre School of Science and Technology, Nottingham Trent University, Nottingham, ENG, United Kingdom
38MacroGenics, Inc., Washington, DC

10:00 AM

Curtis Lachowiez, MD1, Marina Konopleva, MD, PhD2, Tapan M. Kadia, MD3, Naval Daver, MD2,3, Sanam Loghavi, MD4, Sa A Wang, MD4*, Maria Adeoti, R.N.3*, Sherry A. Pierce, BSN, BA3*, Koichi Takahashi, MD, PhD2, Nicholas J. Short, MD2, Koji Sasaki, MD3, Gautam Borthakur, MD3, Ghayas C. Issa, MD2, William G. Wierda, MD, PhD3, Naveen Pemmaraju, MD3, Guillermo Montalban Bravo, MD2, Alessandra Ferrajoli, MD3, Nitin Jain, MD2, Lucia Masarova, MD2*, Musa Yilmaz, MD3, Elias Jabbour, MD3, Guillermo Garcia-Manero, MD3, Steven M. Kornblau, MD2, Farhad Ravandi, MBBS3, Hagop M. Kantarjian, MD3 and Courtney D. Dinardo, MD, MSc3

1Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
4Department of Hematopathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX

10:15 AM

Naval Daver, MD1, Jessica K. Altman, MD2, Joseph Maly, MD3, Mark Levis, MD, PhD4, Ellen Ritchie, MD 5, Mark Litzow, MD6, James K. McCloskey, MD7, Catherine C. Smith, MD8, Gary J. Schiller, MD9, Terrence Bradley, MD10,11*, Ramon V. Tiu, MD12*, Wan-Jen Hong, MD13*, Bo Tong, PhD14*, Qin Qin, MS14*, Kimberley Dilley, MD, MPH14* and Alexander E. Perl, MD15

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Robert H. Lurie Comprehensive Cancer Center, Northwest University, Chicago, IL
3Norton Cancer Institute, Louisville, KY
4Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
5MD Anderson Cancer Center, Science Park-Research Division, Department of Carcinogenesis, The University of Texas, Smithville, TX
6Division of Hematology, Mayo Clinic, Rochester, MN
7John Theurer Cancer Center at Hackensack Meridian Health, Hackensack, NJ
8University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA
9David Geffen School of Medicine at UCLA, Los Angeles, CA
10Department of Medicine, University of Miami, Miami, FL
11Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL
12Astellas Pharma US, Inc., Northbrook, IL
13Genentech, Inc., South San Francisco, CA
14AbbVie Inc., North Chicago, IL
15Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA

10:30 AM

Alexander E. Perl, MD1, Jessica K. Altman, MD2, Naoko Hosono, MD, PhD3, Pau Montesinos, MD, PhD4*, Nikolai A. Podoltsev, MD, PhD5, Giovanni Martinelli, MD6, Catherine C. Smith, MD7, Mark Levis, MD, PhD8, Christoph Röllig, Prof., MD9*, Marco Groß-Langenhoff, PhD10*, Nahla Hasabou, MD11*, Qiaoyang Lu, MS11* and Ramon V. Tiu, MD12*

1Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
2Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL
3University of Fukui, Fukui, Japan
4Hospital Universitari i Politècnic La Fe, Valencia, Spain
5Yale School of Medicine, New Haven, CT
6Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST IRCCS, Meldola, Italy
7University of California - San Francisco, San Francisco, CA
8The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
9Universitätsklinikum Carl Gustav Carus, Dresden, Germany
10Astellas Pharma GmbH, Munich, Germany
11Astellas Pharma US, Northbrook, IL
12Astellas Pharma US, Inc., Northbrook, IL

10:45 AM

Ahmad S. Alotaibi, MD1*, Musa Yilmaz, MD2, Rashmi Kanagal-Shamanna, MD3, Sanam Loghavi, MD4, Tapan M. Kadia, MD2, Courtney D. DiNardo, MD, MSc2, Gautam Borthakur, MD2, Sherry A. Pierce, BSN, BA2*, Sa A Wang, MD3*, Guilin Tang, MD3*, Veronica A Guerra, MD2, Bachar Samra, MD2, Naveen Pemmaraju, MD2, Elias Jabbour, MD2, Nicholas J. Short, MD2, Ghayas C. Issa, MD2, Maro Ohanian, DO2*, Guillermo Garcia-Manero, MD2, Kapil N. Bhalla, MD5, Keyur P. Patel, MBBS, PhD3, Koichi Takahashi, MD, PhD2, Michael Andreeff, MD, PhD6, Jorge E. Cortes, MD7, Marina Konopleva, MD, PhD8, Farhad Ravandi, MBBS2, Hagop M. Kantarjian, MD2 and Naval Daver, MD2

1Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
6Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
7Georgia Cancer Center Augusta University, Augusta, GA
8Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX

*signifies non-member of ASH